Neuren Pharmaceuticals
Home
About Us
Company Overview
Leadership Team
Corporate Directory
Product development
Product Development Pipeline
The science behind Neuren's products
Trofinetide (also known as NNZ-2566) in Rett Syndrome
Trofinetide (also known as NNZ-2566) in Fragile X Syndrome
NNZ-2591 in Phelan-McDermid syndrome
NNZ-2591 in Angelman syndrome
NNZ-2591 in Pitt Hopkins syndrome
Investor Information
Welcome
Share Price Information
Corporate Calendar
Shareholder Services
Corporate Governance
Analyst Coverage
Corporate Directory
News & Reports
ASX Announcements
Annual and Interim Reports
Scientific presentations
Investor presentations, audio, video
Email Alerts
Publications
Contact Us
Contact Us
Email Alerts
Home
>
News & Reports
>
Investor presentations, audio, video
Font Smaller
Font larger
Print Page
Investor presentations, audio, video
29-Jun-2020
AGM Chairman's Address and CEO Presentation
29-May-2020
Podcast interview: Neuren's CEO Jon Pilcher and Scott Power, Morgans 29 May 2020
6-Apr-2020
Corporate presentation, 6 April 2020
